281 related articles for article (PubMed ID: 22119955)
21. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
22. Delivery of siRNA from lyophilized polymeric surfaces.
Andersen MØ; Howard KA; Paludan SR; Besenbacher F; Kjems J
Biomaterials; 2008 Feb; 29(4):506-12. PubMed ID: 17950838
[TBL] [Abstract][Full Text] [Related]
23. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes.
Hossain S; Stanislaus A; Chua MJ; Tada S; Tagawa Y; Chowdhury EH; Akaike T
J Control Release; 2010 Oct; 147(1):101-8. PubMed ID: 20620182
[TBL] [Abstract][Full Text] [Related]
24. Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing.
Baoum A; Ovcharenko D; Berkland C
Int J Pharm; 2012 May; 427(1):134-42. PubMed ID: 21856394
[TBL] [Abstract][Full Text] [Related]
25. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
26. Effect of chitosan chain architecture on gene delivery: comparison of self-branched and linear chitosans.
Malmo J; Vårum KM; Strand SP
Biomacromolecules; 2011 Mar; 12(3):721-9. PubMed ID: 21294570
[TBL] [Abstract][Full Text] [Related]
27. Efficient intracellular siRNA delivery strategy through rapid and simple two steps mixing involving noncovalent post-PEGylation.
Kong WH; Sung DK; Shim YH; Bae KH; Dubois P; Park TG; Kim JH; Seo SW
J Control Release; 2009 Sep; 138(2):141-7. PubMed ID: 19426771
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles.
Pittella F; Miyata K; Maeda Y; Suma T; Watanabe S; Chen Q; Christie RJ; Osada K; Nishiyama N; Kataoka K
J Control Release; 2012 Aug; 161(3):868-74. PubMed ID: 22580114
[TBL] [Abstract][Full Text] [Related]
29. Chitosan Nanoparticles for SiRNA Delivery In Vitro.
Ragelle H; Vanvarenberg K; Vandermeulen G; Préat V
Methods Mol Biol; 2016; 1364():143-50. PubMed ID: 26472448
[TBL] [Abstract][Full Text] [Related]
30. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study.
Zheng F; Shi XW; Yang GF; Gong LL; Yuan HY; Cui YJ; Wang Y; Du YM; Li Y
Life Sci; 2007 Jan; 80(4):388-96. PubMed ID: 17074366
[TBL] [Abstract][Full Text] [Related]
31. In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines.
Salva E; Akbuğa J
Pharmazie; 2010 Dec; 65(12):896-902. PubMed ID: 21284259
[TBL] [Abstract][Full Text] [Related]
32. Lipoplexes versus nanoparticles: pDNA/siRNA delivery.
Khurana B; Goyal AK; Budhiraja A; Aora D; Vyas SP
Drug Deliv; 2013 Feb; 20(2):57-64. PubMed ID: 23537464
[TBL] [Abstract][Full Text] [Related]
33. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
34. Comparison of chitosan/siRNA and trimethylchitosan/siRNA complexes behaviour in vitro.
Dehousse V; Garbacki N; Jaspart S; Castagne D; Piel G; Colige A; Evrard B
Int J Biol Macromol; 2010 Apr; 46(3):342-9. PubMed ID: 20096725
[TBL] [Abstract][Full Text] [Related]
35. Novel hyaluronic acid-chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis.
Lu HD; Zhao HQ; Wang K; Lv LL
Int J Pharm; 2011 Nov; 420(2):358-65. PubMed ID: 21911044
[TBL] [Abstract][Full Text] [Related]
36. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of efficiencies of the cellular uptake and gene silencing of chitosan/siRNA complexes via the inclusion of a negatively charged poly(γ-glutamic acid).
Liao ZX; Ho YC; Chen HL; Peng SF; Hsiao CW; Sung HW
Biomaterials; 2010 Nov; 31(33):8780-8. PubMed ID: 20800274
[TBL] [Abstract][Full Text] [Related]
38. Gene silencing activity of siRNA polyplexes based on thiolated N,N,N-trimethylated chitosan.
Varkouhi AK; Verheul RJ; Schiffelers RM; Lammers T; Storm G; Hennink WE
Bioconjug Chem; 2010 Dec; 21(12):2339-46. PubMed ID: 21049986
[TBL] [Abstract][Full Text] [Related]
39. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
40. Structural contributions of blocked or grafted poly(2-dimethylaminoethyl methacrylate) on PEGylated polycaprolactone nanoparticles in siRNA delivery.
Lin D; Huang Y; Jiang Q; Zhang W; Yue X; Guo S; Xiao P; Du Q; Xing J; Deng L; Liang Z; Dong A
Biomaterials; 2011 Nov; 32(33):8730-42. PubMed ID: 21885115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
